Historical Valuation
PTC Therapeutics Inc (PTCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.00 is considered Undervalued compared with the five-year average of -12.43. The fair price of PTC Therapeutics Inc (PTCT) is between 105.26 to 128.33 according to relative valuation methord. Compared to the current price of 76.35 USD , PTC Therapeutics Inc is Undervalued By 27.47%.
Relative Value
Fair Zone
105.26-128.33
Current Price：76.35
27.47%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
PTC Therapeutics Inc (PTCT) has a current Price-to-Book (P/B) ratio of -39.38. Compared to its 3-year average P/B ratio of -9.47 , the current P/B ratio is approximately 315.77% higher. Relative to its 5-year average P/B ratio of 89.65, the current P/B ratio is about -143.93% higher. PTC Therapeutics Inc (PTCT) has a Forward Free Cash Flow (FCF) yield of approximately 11.45%. Compared to its 3-year average FCF yield of -2.57%, the current FCF yield is approximately -545.17% lower. Relative to its 5-year average FCF yield of -5.16% , the current FCF yield is about -321.98% lower.
P/B
Median3y
-9.47
Median5y
89.65
FCF Yield
Median3y
-2.57
Median5y
-5.16
Competitors Valuation Multiple
AI Analysis for PTCT
The average P/S ratio for PTCT competitors is 31.60, providing a benchmark for relative valuation. PTC Therapeutics Inc Corp (PTCT.O) exhibits a P/S ratio of 7.00, which is -77.85% above the industry average. Given its robust revenue growth of 7.23%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PTCT
1Y
3Y
5Y
Market capitalization of PTCT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PTCT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PTCT currently overvalued or undervalued?
PTC Therapeutics Inc (PTCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.00 is considered Undervalued compared with the five-year average of -12.43. The fair price of PTC Therapeutics Inc (PTCT) is between 105.26 to 128.33 according to relative valuation methord. Compared to the current price of 76.35 USD , PTC Therapeutics Inc is Undervalued By 27.47% .
What is PTC Therapeutics Inc (PTCT) fair value?
PTCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of PTC Therapeutics Inc (PTCT) is between 105.26 to 128.33 according to relative valuation methord.
How does PTCT's valuation metrics compare to the industry average?
The average P/S ratio for PTCT's competitors is 31.60, providing a benchmark for relative valuation. PTC Therapeutics Inc Corp (PTCT) exhibits a P/S ratio of 7.00, which is -77.85% above the industry average. Given its robust revenue growth of 7.23%, this premium appears unsustainable.
What is the current P/B ratio for PTC Therapeutics Inc (PTCT) as of Jan 12 2026?
As of Jan 12 2026, PTC Therapeutics Inc (PTCT) has a P/B ratio of -39.38. This indicates that the market values PTCT at -39.38 times its book value.
What is the current FCF Yield for PTC Therapeutics Inc (PTCT) as of Jan 12 2026?
As of Jan 12 2026, PTC Therapeutics Inc (PTCT) has a FCF Yield of 11.45%. This means that for every dollar of PTC Therapeutics Inc’s market capitalization, the company generates 11.45 cents in free cash flow.
What is the current Forward P/E ratio for PTC Therapeutics Inc (PTCT) as of Jan 12 2026?
As of Jan 12 2026, PTC Therapeutics Inc (PTCT) has a Forward P/E ratio of -50.06. This means the market is willing to pay $-50.06 for every dollar of PTC Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for PTC Therapeutics Inc (PTCT) as of Jan 12 2026?
As of Jan 12 2026, PTC Therapeutics Inc (PTCT) has a Forward P/S ratio of 7.00. This means the market is valuing PTCT at $7.00 for every dollar of expected revenue over the next 12 months.